VARUBI

Peak

rolapitant hydrochloride

TerSera Therapeutics

NDAINTRAVENOUSEMULSION

Approved

Oct 2017

Lifecycle

Peak

Competitive Pressure

0/100

Loss of Exclusivity

LOE Date

Jul 14, 2032

77 months away

Patent Expiry

Jul 14, 2032

Patent Records (5)

Patent #	Expiry	Type	Use Code
7981905	Apr 4, 2027		U-1741
8178550	Apr 4, 2027	SubstanceProduct	—
8404702	Apr 4, 2027		U-1741
7049320	Aug 19, 2028	SubstanceProduct	U-1741
8470842	Jan 18, 2029		U-1741

Company

TerSera Therapeutics

External Resources

Full prescribing information

FDA approval history

Drug nomenclature & identifiers